Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Amphastar

Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum

On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, 100mg/5mL, and 200mg/10mL in single-dose vials, previously referred to as AMP-002.

Benzinga

Will Eli Lilly's Emergency Diabetes Drug Give Amphastar Wings?

AMPH stock has doubled so far this year and is in a buy zone again. It earlier bought Eli Lilly's emergency diabetes drug which can drive future growth.

Investors Business Daily

Amphastar, Stock Of The Day, Breaks Out As It Sees Upside From Eli Lilly Deal

Amphastar is IBD Stock Of The Day as the biotech stock revs up marketing of Baqsimi, a drug purchased this year from Eli Lilly.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

IBD 50 Stock Hits All-Time High, And 44% EPS Growth Expected

This drug stock ranks first out of 790 medical stocks and is in the buy zone. The company plans to roll out its overdose nasal spray in the third quarter.

Investors Business Daily

Why No. 1 Biotech Amphastar Crashed As Runaway Syndax Hit A Profit-Taking Zone

Top-ranked biotech stock Amphastar crashed Tuesday after the company received its second Food and Drug Administration rejection since June.

Investors Business Daily

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

The top five biotech stocks today have several commonalities. Among them are strong ratings. Some show promising charts and are Tech Leaders.

Investors Business Daily

Amphastar Pharmaceuticals Stock Scores Composite Rating Climb To 96

Amphastar Pharmaceutcls saw an improvement in its IBD SmartSelect Composite Rating Thursday, from 94 to 96.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Dow Jones, Nasdaq Finish Higher After Weak Opening; Growth Stocks Outperform While Oil Plays Near Buy Points

The Dow Jones and other major indexes strengthened into the close after opening lower. Growth stocks took the lead and outperformed.

Investors Business Daily

Dow Jones Climbs Off Lows, Led By Salesforce Stock; Fast-Growing Amphastar Scores Bullish Breakout

The Dow Jones pared early losses Tuesday, along with the Nasdaq and S&P 500, as oil and gas stocks outperformed again.

Investors Business Daily

IBD 50 Stocks To Watch: Why Top Biotech Stock Amphastar Deserves Closer Look

Amphastar Pharmaceuticals is the leading biotech stock, ranking first out of 799 companies in the industry.

Investors Business Daily

Why Top-Rated IBD 50 Stock Amphastar Pharmaceuticals Added To Its 75% Run

Biotech stock Amphastar hit a record high Friday after U.S. officials approved its generic version of an Organon infertility drug.

Investors Business Daily

Amphastar's Generic Ganirelix Acetate Injection Scores FDA Approval

The FDA has approved Amphastar Pharmaceuticals Inc's (NASDAQ:AMPH) Abbreviated New Drug Application for Ganirelix Acetate Injection, 250mg/0.5mL in a prefilled syringe. Ganirelix acetate injection is indicated to inhibit premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation. The FDA determined Amphastar's ganirelix is bioequivalent and therapeutically equivalent to Organon & Co's (NYSE:OGN) Ganirelix…

Organisations

Department of Defense

Amphastar Pharmaceuticals

11 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

303,601 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.